Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03313037 · ClinicalTrials.gov registry record · Phase 2
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 444
- Enrollment target
NCT03313037 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 444 participants.
The verdict
NCT03313037, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 444 participants
- Enrollment target
Study Summary
This is a Phase 2, randomized, double-blinded study with a 2-arm parallel design. Healthy adults aged 60 through 64 years of age with no history of pneumococcal vaccination will be randomized equally to receive either a single intramuscular dose of multivalent pneumococcal conjugate vaccine followed 1 month later with a dose of saline or Prevnar 13 followed 1 month later with a dose of PPSV23 (control group).
Interventions
- OTHER Saline
- BIOLOGICAL Prevnar 13
- BIOLOGICAL Multivalent
- BIOLOGICAL PPSV23
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2017-10-10 |
| Est. Completion | 2018-12-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03313037
The ClinicalTrials.gov registry entry for NCT03313037 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 444 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Saline is the first listed.
NCT03313037 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03313037 about?
NCT03313037 is a clinical study titled "Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age". This is a Phase 2, randomized, double-blinded study with a 2-arm parallel design. Healthy adults aged 60 through 64 years of age with no history of pneumococcal vaccination will be randomized equally to receive either a single intramuscular dose of multivalent pneumococcal conjugate vaccine followed...
What is the current status of trial NCT03313037?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 444 participants. The study started on 2017-10-10. Estimated completion is 2018-12-10.
What interventions are being tested in trial NCT03313037?
The interventions under investigation include: Saline (OTHER), Prevnar 13 (BIOLOGICAL), Multivalent (BIOLOGICAL), PPSV23 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03313037?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.